International Guillain‐Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain‐Barré syndrome

• DOI: 10.1111/jns.12209
• Publication Date: 2017-04-13T11:53:44Z
• Authors: Bart C. Jacobs; Bianca van den Berg; Christine Verboon; Govindsinh Chavada; David R. Cornblath; Kenneth C. Gorson; Thomas Harbo; Hans‐Peter Hartung; Richard A. C. Hughes; Susumu Kusunoki; Pieter A. van Doorn; Hugh J. Willison
• Keywords: Male; EMC MM-02-72-02; PROGNOSIS; diagnosis; International Cooperation; 610; Guillain-Barre syndrome; DIAGNOSIS; Guillain-Barre Syndrome; CLASSIFICATION; VALIDATION; Cohort Studies; 03 medical and health sciences; 0302 clinical medicine; INFECTION; Outcome Assessment, Health Care; CRITERIA; INTRAVENOUS IMMUNOGLOBULIN; Humans; treatment; biomarkers; biomarkers; diagnosis; Guillain-Barré syndrome; outcome; prognosis; treatment; Neuroscience (all); Neurology (clinical); 3. Good health; biomarkers; diagnosis; Guillain-Barré syndrome; outcome; prognosis; treatment;; diagnosi; Settore MED/26 - NEUROLOGIA; Observational Studies as Topic; Guillain-Barré syndrome; biomarkers; diagnosis; outcome; prognosis; treatment; ANTIBODIES; biomarkers; diagnosis; Guillain-Barré syndrome; outcome; prognosis; treatment; Neuroscience (all); Neurology (clinical); outcome; Disease Progression; Guillain-Barré syndrome; biomarker; Female; prognosis; COLLECTION; prognosi

Abstract Guillain‐Barré syndrome (GBS) is an acute polyradiculoneuropathy with a highly variable clinical presentation, course, and outcome. The factors that determine the variation of GBS are poorly understood which complicates care treatment individual patients. protocol ongoing International Outcome Study (IGOS), prospective, observational, multicenter cohort study aims to identify biological determinants predictors disease onset, subtype, course outcome presented here. Patients fulfilling diagnostic criteria for GBS, regardless age, severity, variant forms, or treatment, can participate if included within 2 weeks after onset weakness. Information about demography, preceding infections, features, findings, collected. In addition, cerebrospinal fluid serial blood samples serum DNA collected at standard time points. original aim was include least 1,000 patients follow‐up 1–3 years. Data via web‐based data entry system stored anonymously. IGOS started in May 2012 by January 2017 more than 1,400 participants from 143 active centers 19 countries across 5 continents. data/biobank available research projects conducted expertise groups focusing on specific topics including epidemiology, criteria, clinimetrics, electrophysiology, antecedent events, antibodies, genetics, prognostic modeling, effects, long‐term GBS. will help standardize international collection biosamples future